COMP <GO>
PAHC vs RARE // NET PROFIT MARGIN
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Ultragenyx Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: PAHC 8
— RARE 1
▲ NET PROFIT MARGIN LEADER: PAHC
LAST: $38.74 (-0.36%) • MKT CAP: $1.58B
net-margins
3.70%
LAST: $16.30 (+1.24%) • MKT CAP: $1.59B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. RARE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | RARE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -35.00% | +44.90 | PAHC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.2x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 8.50% | -60.00% | +68.50 | PAHC | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 3.70% | -60.00% | +63.70 | PAHC | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 20.20% | +7.20 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.00% | +1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 0.20 | +2.67 | PAHC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 3/9 | +5.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 49.5 | +7.40 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $1.59B | -$8.7M | RARE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | RARE REV | PAHC GROSS % | RARE GROSS % | PAHC FCF | RARE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $673.0M | 30.9% | — | $80.1M | -$472.0M |
| FY 2024 | $1.02B | $560.0M | 30.8% | — | $87.6M | -$421.0M |
| FY 2023 | $977.9M | $434.0M | — | — | $13.3M | -$475.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
RARE // BETA —